Sewa S. Legha

Q: What Schools Are Affiliated With Sewa S. Legha

Sewa S. Legha is affiliated with the following schools: MD Anderson Cancer Center, Baylor College of Medicine

Sewa S. Legha's AcademicInfluence.com Rankings

Sewa S. Legha

Medical

#3418

World Rank

#3886

Historical Rank

Cardiology

#363

World Rank

#374

Historical Rank

Pharmacology

#428

World Rank

#481

Historical Rank

medical Degrees

Sewa S. Legha

Philosophy

#9771

World Rank

#13377

Historical Rank

Logic

#6727

World Rank

#8272

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Why Is Sewa S. Legha Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Sewa S. Legha's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. (1982) (744)
Tamoxifen in the treatment of breast cancer. (1988) (621)
Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. (2002) (358)
Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system. (1997) (299)
Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. (1998) (284)
Prognostic factors in metastatic breast cancer treated with combination chemotherapy. (1979) (281)
A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving Adriamycin. (1984) (237)
Treatment of uveal melanoma metastatic to the liver. A review of the M. D. Anderson cancer center experience and prognostic factors (1995) (236)
Prognostic factors for survival of patients treated systemically for disseminated melanoma. (1998) (219)
Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. (1998) (199)
Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha. (1996) (174)
A prospective evaluation of a triple‐drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma (1989) (169)
A phase II trial of taxol in metastatic melanoma (1990) (168)
Multivariate analysis of prognostic factors in metastatic breast cancer. (1983) (154)
Pleural mesothelioma: clinical features and therapeutic implications. (1977) (152)
Systemic treatments for advanced cutaneous melanoma. (1995) (148)
Treatment of uveal melanoma metastatic to the liver: a review of the M. D. Anderson Cancer Center experience and prognostic factors. (1996) (131)
Evaluation of high-dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units: a prospective randomized study. (1987) (129)
Vulvar melanoma at the M. D. Anderson Cancer Center: 25 years later (2001) (127)
Doxorubicin‐induced congestive heart failure in adults (1985) (116)
CLINICAL AND PHARMACOLOGIC INVESTIGATION OF THE EFFECTS OF α‐TOCOPHEROL ON ADRIAMYCIN CARDIOTOXICITY * (1982) (114)
Uveal melanoma: natural history and treatment options for metastatic disease. (1999) (114)
Chemotherapy for metastatic merkel cell carcinoma. Review of the M. D. Anderson hospital's experience (1988) (113)
Role of computed tomography in the staging of patients with local-regional metastases of melanoma. (1995) (111)
Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma. (2006) (106)
Evaluation of AMSA in previously treated patients with acute leukemia: results of therapy in 109 adults. (1982) (104)
Vincristine Neurotoxicity (1986) (102)
Prognostic value of size of lymph node metastases in patients with cutaneous melanoma. (1995) (100)
Hormonal therapy of breast cancer: new approaches and concepts. (1978) (99)
Pulmonary toxicity of mitomycin (1980) (96)
Design and results of phase I cancer clinical trials: three-year experience at M.D. Anderson Cancer Center. (1996) (94)
Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy. (1995) (93)
Complete remissions in metastatic breast cancer treated with combination drug therapy. (1979) (93)
4'-(9-Acridinylamino) methanesulfon-m-anisidide (AMSA): a new drug effective in the treatment of adult acute leukemia. (1980) (92)
Hexamethylmelamine. An evaluation of its role in the therapy of cancer (1976) (91)
Adriamycin therapy by continuous intravenous infusion in patients with metastatic breast cancer (1982) (89)
Interferons in the treatment of malignant melanoma. A review of recent trials (1986) (87)
Single-agent ifosfamide studies in sarcomas of soft tissue and bone: the M.D. Anderson experience. (1993) (84)
Phase 1 clinical investigation of 4'-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992), a new acridine derivative. (1978) (80)
High-dose cisplatin administration without hypertonic saline: observation of disabling neurotoxicity. (1985) (76)
Antiestrogens in the treatment of breast cancer. (1976) (71)
Development and results of biochemotherapy in metastatic melanoma: the University of Texas M.D. Anderson Cancer Center experience. (1997) (71)
Phase II study of neoadjuvant concurrent biochemotherapy in melanoma patients with local‐regional metastases (1998) (71)
Clinical evaluation of recombinant interferon alfa-2a (Roferon-A) in metastatic melanoma using two different schedules . (1987) (68)
Phase I study of taxol using a 5-day intermittent schedule. (1986) (67)
Fluorouracil, doxorubicin, cyclophosphamide, and cisplatin combination chemotherapy in advanced or recurrent salivary gland carcinoma. (1990) (67)
Evaluation of interleukin‐2 administered by continuous infusion in patients with metastatic melanoma (1996) (67)
Management of breast cancer patients failing adjuvant chemotherapy with adriamycin‐containing regimens (1981) (66)
Adjuvant chemotherapy for advanced nasopharyngeal carcinoma (1987) (63)
Tamoxifen‐induced hypercalcemia in breast cancer (1981) (60)
Phase I clinical investigation of homoharringtonine. (1984) (58)
Therapeutic approaches in malignant mesothelioma. (1977) (55)
Adriamycin and mitomycin C: possible synergistic cardiotoxicity. (1978) (53)
Phase II trial of doxil for patients with metastatic melanoma refractory to frontline therapy. (1999) (49)
Role of recombinant interleukin-2 in combination with interferon-alfa and chemotherapy in the treatment of advanced melanoma. (1993) (47)
High-dose induction chemotherapy of metastatic breast cancer in protected environment: a prospective randomized study. (1987) (45)
The role of interferon alfa in the treatment of metastatic melanoma. (1997) (43)
Nafoxidine–‐an antiestrogen for the treatment of breast cancer (1976) (42)
Human pharmacokinetics of a new acridine derivative, 4'-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992). (1983) (41)
Phase I trial of subcutaneous recombinant human interleukin‐2 in patients with metastatic melanoma (2002) (40)
Radioimaging of melanoma using 99mTc-labeled Fab fragment reactive with a high molecular weight melanoma antigen. (1990) (39)
Enhancement of cell-mediated immunity in melanoma patients immunized with murine anti-idiotypic monoclonal antibodies (MELIMMUNE) that mimic the high molecular weight proteoglycan antigen. (1998) (38)
Acute rhabdomyolysis after concurrent administration of interleukin‐2, interferon‐alfa, and chemotherapy for metastatic melanoma (1995) (37)
Chemotherapy for metastatic carcinoid tumors: experiences with 32 patients and a review of the literature. (1977) (36)
Phase Ia/Ib trial of anti-GD2 chimeric monoclonal antibody 14.18 (ch14.18) and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in metastatic melanoma. (1996) (36)
Pharmacokinetics and metabolism of the antitumor drug amonafide (NSC-308847) in humans. (1987) (35)
Tamoxifen. Use in treatment of metastatic breast cancer refractory to combination chemotherapy. (1979) (35)
Current therapy for malignant melanoma. (1989) (35)
Cytotoxic chemotherapy in adrenal cortical carcinoma. (1980) (34)
A randomized phase III trial of biochemotherapy versus interferon-&agr;-2b for adjuvant therapy in patients at high risk for melanoma recurrence (2009) (34)
Evaluation of silicone elastomer catheters for long-term intravenous chemotherapy. (1985) (34)
Phase II study of thalidomide in patients with metastatic melanoma (2004) (32)
Neurologic and cardiac rhythm abnormalities associated with 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) therapy. (1979) (30)
Initial experience with AMSA as single agent treatment against malignant lymphoproliferative disorders. (1981) (30)
Active immunotherapy with ultraviolet B-irradiated autologous whole melanoma cells plus DETOX in patients with metastatic melanoma. (1998) (30)
Phase II trial of tirapazamine combined with cisplatin in chemotherapy of advanced malignant melanoma. (1997) (28)
Chemoimmunotherapy for meningeal melanocytoma of the thoracic spinal cord. Report of a case. (1979) (28)
Adjuvant chemotherapy in lung cancer. Review and prospects (1977) (25)
Study of Tumor-Infiltrating Lymphocytes for Adoptive Therapy of Renal Cell Carcinoma (RCC) and Metastatic Melanoma: Sequential Proliferation of Cytotoxic Natural Killer and Noncytotoxic T Cells in RCC (1991) (25)
Phase I study of spirogermanium given daily. (1983) (25)
Phase II study of recombinant alpha-interferon in malignant melanoma. (1990) (25)
Combination of chemotherapy with interleukin-2 and interferon-alfa for the treatment of advanced melanoma. (1994) (24)
Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with interferon alpha and chemotherapy. (1997) (23)
Phase I clinical investigation of benzisoquinolinedione. (1987) (23)
Neocarzinostatin (NSC 157365) a new cancerostatic compound. (1976) (23)
Phase II studies of homoharringtonine in patients with advanced malignant melanoma; sarcoma; and head and neck, breast, and colorectal carcinomas. (1986) (23)
Phase II study of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in metastatic breast cancer. (1979) (22)
Response to hormonal therapy as a prognostic factor for metastatic breast cancer treated with combination chemotherapy (1980) (22)
Ifosfamide versus cyclophosphamide in combination drug therapy for metastatic breast cancer. (1979) (22)
Pilot study of preoperative chemotherapy with cisplatin, vinblastine, and dacarbazine in patients with local‐regional recurrence of melanoma (1994) (21)
Clinical pharmacology of trimetrexate (1987) (21)
Phase II trial of escalated dose of tirapazamine combined with cisplatin in advanced malignant melanoma. (1999) (19)
Phase I trial of 1-(2′-deoxy-2′-fluoro-1-beta-D-arabinofuranosyl)-5-methyluracil (FMAU) terminated by severe neurologic toxicity (1989) (19)
Spontaneous Rupture of Spleen in a Patient with Splenic Metastasis of Melanoma. A Case Report (1992) (19)
Treatment of advanced breast cancer with aminoglutethimide after therapy with tamoxifen (1982) (18)
Selective localization of 4'-(9-acridinylamino)-methanesulfon-m-anisidide in B 16 melanoma. (1978) (18)
Nitric oxide and neopterin levels and clinical response in stage III melanoma patients receiving concurrent biochemotherapy (1998) (18)
Prognostic value of prechemotherapy skin tests in patients with metastatic breast carcinoma (1981) (17)
Phase II trial of m-AMSA in hepatocellular carcinoma: a Southwest Oncology Group Study. (1982) (17)
A Phase II study of “decrescendo” interleukin‐2 plus interferon‐α‐2a in patients with progressive metastatic melanoma after chemotherapy (2000) (16)
Adjuvant chemotherapy with fluorouracil, doxorubicin and cyclophosphamide (FAC) in stage II or III breast cancer; 5-year results (1981) (16)
Prediction of complete remission in patients with refractory acute leukemia treated with AMSA. (1984) (15)
Letter: Antiestrogens in the treatment of cancer. (1976) (15)
Phase II clinical evaluation of intravenous 4'-(9-acridinylamino)methanesulfon-m-anisidide in colorectal cancer. (1983) (15)
Tamoxifen in breast cancer. (1978) (15)
Treatment of brain metastases from melanoma. (2005) (14)
Hormonal therapy with tamoxifen in male breast cancer. (1979) (14)
Clinical pharmacokinetics of the new antitumor agent AMSA (1979) (14)
Reduction of adriamycin cardiac toxicity using a prolonged continuous intravenous infusion (1981) (14)
Phase II study of alpha-interferon and 13-cis-retinoic acid in metastatic melanoma (1993) (13)
Acute cyclophosphamide hypersensitivity reaction: possible lack of cross-sensitivity to mechlorethamine and isophosphamide. (1978) (12)
Intraarterial infusion chemotherapy in regionally advanced malignant melanoma (1990) (12)
Hormone receptors in breast cancer and response to chemotherapy. (1979) (12)
Ventricular fibrillation following AMSA. Uncomplicated retreatment following correction of hypokalemia (1983) (11)
Phase II study of high-dose amsacrine (AMSA) and autologous bone marrow transplantation in patients with refractory metastatic breast cancer. (1983) (11)
Phase II study of 4'-(9-acridinylamino) methanesulfon-m- anisidide (AMSA) in metastatic melanoma. (1980) (11)
High-dose AMSA and bone marrow rescue in patients with solid tumors. (1982) (11)
Phase I clinical trial and pharmacokinetic evaluation of 4′-0-tetrahydropyranyladriamycin (THP-adriamycin) (1989) (10)
Clinical studies with rubidazone. (1979) (10)
Continuous-Infusion Adriamycin (1986) (10)
Phase I trial of caracemide using bolus and infusion schedules. (1987) (10)
Peptichemio versus melphalan (L‐PAM) in advanced breast cancer (1982) (10)
Chemoimmunotherapy for metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, methotrexate, L-asparaginase, Corynebacterium parvum, and Pseudomonas vaccine. (1980) (9)
Pilot study of intra-arterial cisplatin and intravenous vinblastine and dacarbazine in patients with melanoma in-transit metastases. (1999) (9)
Systemic therapy of metastatic breast cancer: a review of the current trends. (1982) (9)
The Phase I Study: General Objectives, Methods, and Evaluation (1987) (9)
Interlenkin-2 alone and in combination with other cytokines in melanoma: the investigational approach at the University of Texas M. D. Anderson Cancer Center (1989) (9)
Adriamycin Cardiac Toxicity — An Assessment of Approaches to Cardiac Monitoring and Cardioprotection (1988) (8)
A phase II open-label trial of apomine (SR-45023A) in patients with refractory melanoma (2006) (8)
Augmentation of adriamycin's therapeutic index by prolonged continuous i.v. infusion for advanced breast cancer (1979) (8)
A phase III randomized trial of adjuvant biochemotherapy (BC) versus interferon-α-2b (IFN) in patients (pts) with high risk for melanoma recurrence. (2006) (8)
Efficacy of ondansetron against nausea and vomiting caused by dacarbazine‐containing chemotherapy (1992) (8)
Clinical pharmacokinetics of ifosfamide in combination with N‐acetylcysteine (1992) (8)
PHASE I TRIAL OF MURINE ANTI-GANGLIOSIDE (GD2) MONOCLONAL ANTIBODY (Mab) 14G2A IN CANCER PATIENTS (1992) (8)
Phase I study of hycanthone. (1978) (8)
Phase II study of hexamethylmelamine alone and in combination with mitomycin C and vincristine in advanced breast carcinoma. (1979) (8)
Mechanism of the anti-tumour effect of biochemotherapy in melanoma: preliminary results. (1994) (7)
Sequential methotrexate, 5-fluorouracil, and cisplatin in the treatment of recurrent squamous-cell carcinoma of the head and neck: failure of hypertonic saline to reduce the nephrotoxicity of cisplatin. (1986) (7)
Phase II Study of Recombinant α‐Interferon in Malignant Melanoma (1990) (7)
Pulmonary toxicity associated with spirogermanium. (1984) (7)
m‐AMSA in epithelial carcinoma of the ovary A Southwest Oncology Group study (1983) (6)
A Phase I trial of weekly lomustine in patients with advanced cancer (1994) (6)
Phase II evaluation of vinblastine, methotrexate, and calcium leukovorin rescue in patients with refractory metastatic breast cancer (1983) (6)
Role of Adriamycin in Breast Cancer and Sarcomas (1982) (6)
Mitotane failure in adrenocortical cancer: Where next? (1993) (6)
AMSA: A new acridine derivative with activity against metastatic melanoma (1979) (6)
Phase II study of vindesine and dacarbazine with or without non-specific stimulation of the immune system in patients with metastatic melanoma. (1993) (6)
Detorubicin--an active anthracycline in untreated metastatic melanoma. (1985) (6)
DNA damage in peripheral blood mononuclear cells correlates with response to biochemotherapy in melanoma (1998) (5)
Phase II evaluation of AMSA in adult sarcomas. (1981) (5)
Phase II study of spirogermanium in the treatment of metastatic breast cancer. (1984) (4)
Immunological properties of melanoma tumor-infiltrating lymphocytes before and after IL-2-based biotherapies. (1991) (4)
A review of mitomycin regimens in advanced breast cancer therapy. (1985) (4)
Biochemotherapy using interleukin-2 + interferon alpha-2a (IFN) in combination with cisplatin (C), vinblastine (V) and DTIC (D) in patients with metastatic melanoma: 113 (1993) (4)
Phase I studies of trimetrexate using single and weekly dose schedules (1991) (4)
Hepatotoxicity of hycanthone in patients with metastatic breast cancer. (1980) (4)
Zinostatin-related pulmonary toxicity. (1981) (4)
Combination chemotherapy of metastatic breast carcinoma with cyclophosphamide, adriamycin, and peptichemio (1984) (4)
Alteration in interactions between tumor-infiltrating lymphocytes and tumor cells in human melanomas after chemotherapy or immunotherapy (1991) (3)
Long-term clinical results of the combination of cisplatin (C), vinblastine (V), DTIC (D) and interferon-alfa (I) with or without tamoxifen (T) for metastatic melanoma. (2006) (3)
Amsacrine (m-AMSA) in squamous cell carcinoma of the uterine cervix: a Southwest Oncology Group study. (1984) (3)
Phase II trial of amsacrine in pancreatic carcinoma: a Southwest Oncology Group study. (1984) (3)
Rubidazone in metastatic breast cancer. (1979) (3)
Interleukin-2 alone and in combination with other cytokines in melanoma: the investigational approach at the University of Texas M.D. Anderson Cancer Center. (1989) (3)
Reutilization of adriamycin in previously treated patients (1981) (3)
Therapy of advanced breast cancer. (1977) (3)
Treating metastatic melanoma: further considerations. (2009) (2)
18 Preoperative chemotherapy with cisplatin, vinblastine and dacarbazine (CVD) in patients with local-regional recurrence of melanoma (AJCC stage-HI) (1995) (2)
Doxorubicin toxicity. (1981) (2)
Differences in nativity, age and gender may impact health behavior and perspectives among Asian Indians (2019) (2)
Phase II trial of amsacrine in metastatic or locally recurrent squamous cell carcinoma from head and neck primaries: a Southwest Oncology Group study. (1984) (2)
Evaluation of α-tocopherol against adriamycin cardiotoxicity in humans (1981) (2)
AMSA toxicity in patients with abnormal liver function. (1981) (2)
Reduction of adriamycin cardiotoxicity by continuous IV infusion: The effect of duration of infusion on cardiotoxicity (1982) (2)
High-dose AMSA and autologous bone marrow transplantation in relapsed acute leukemia. (1982) (2)
Phase II trial of tirapazamine (escalated dose) plus cisplatin in patients with advanced melanoma: 024 (1997) (1)
Reduction of Adriamycin Cardiac Toxicity by Schedule Manipulation (1982) (1)
Correction: Dosage of Thioguanine (1975) (1)
MITOTANE FAILURE IN ADRENOCORTICAL CANCER : WHERE NEXT ? AUTHOR'S REPLY (1993) (1)
m-AMSA and adenocarcinoma of the endometrium (2004) (1)
Biochemotherapy studies in the treatment of advanced melanoma: 081 (1997) (1)
Re: Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. (1995) (1)
m-AMSA: a new anticancer agent. (1980) (1)
Malignant Melanoma: Biology, Diagnosis, and Management (2005) (1)
m-AMSA and adenocarcinoma of the endometrium. A Southwest Oncology Group study. (1984) (1)
Pre-treatment characteristics predictive of complete remission in patients with relapsed acute leukemia treated with AMSA (1982) (1)
Peptichemio in treatment of advanced refractory breast cancer - A phase II study (1979) (1)
Phase II study of PCNU in the treatment of head and neck carcinoma. (1984) (1)
AMSA and peptichemio in the treatment of advanced metastatic breast cancer: A phase II study (1982) (1)
Nitric oxide (NO), neopterin, and cytokine levels versus clinical response in stage III melanoma patients receiving concurrent biochemotherapy: 390 (1997) (0)
Antiestrogens in the treatment of cancer. (Letter to the editor) (1976) (0)
18 Adjuvant biochemotherapy for patients with stage-III melanoma: a pilot study (2004) (0)
Drug-associated cardiotoxicity. (1979) (0)
Evaluation of Silicone Elastomer Catheters for Long-Term Intravenous Chemotherapy (1985) (0)
A PHASE I-II evaluation of trioxifene mesylate in the treatment of advanced breast cancer (1981) (0)
600 Improved remission rate and duration of remission associated with hormone-adriamycin chemotherapy (1983) (0)
Antlestrogens in the treatment of breast cancer (1976) (0)
Books Received (1994) (0)
18 Results of biochemotherapy in the treatment of advanced melanoma,The M.D. Anderson Cancer Center Experience (1997) (0)
Phase I evaluation of Hepatic arterial infusion of interferon alfa-2b in patients with liver cancer (1996) (0)
Therapy of advanced melanoma, Philip Rumke MD (Ed.). S. Karger, Basel (1990), 230 pages. $132.00. (1991) (0)
Treatment of brain metastases from melanoma. Author's reply (2005) (0)
Basic Science of Cancer (2001) (0)
19 Potential of interleukin-2 in the future adjuvant therapy for high-risk melanoma (1999) (0)
Role of chemotherapy in advanced melanoma (2007) (0)
INV 19 Role of chemotherapy in advanced melanoma (2007) (0)
Summary of trials involving high dose IL-2 in patients with advanced melanoma: 407 (1997) (0)
Phase II study of AMSA alone and in combination with DTIC in patients with metastatic melanoma (1988) (0)
Tamoxifen in breast cancer (1986) (0)
Remission and survival data of metastatic breast cancer patients (PTS) achieving complete remission (CR) with combination chemoimmunotherapy (CI) (1978) (0)
Advances in the Diagnosis and Treatment of Malignant Melanoma (1997) (0)
What is the best new anti-melanoma therapy?: 153 (1997) (0)
Novel Strategies for the Treatment of Melanoma (2007) (0)
Cutaneous melanoma. (1992) (0)
Impact of regional (ia) vs systemic (iv) therapy (rx) on survival of patients (pts) with liver metastasis (lm) from choroidal malignant melanoma (cmm): 378 (1993) (0)
Emerging therapies for melanoma (2013) (0)
United States Patent ( 19 ) Canetta et al . 54 METHOD FOR EFFECTING TUMIOR REGRESSION WITH A LOW DOSE (2017) (0)
Evaluation of tamoxifen in chemotherapy resistant metastatic breast cancer (1978) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Sewa S. Legha?

Sewa S. Legha is affiliated with the following schools:

Sewa S. Legha's Academic­Influence.com Rankings

Why Is Sewa S. Legha Influential?

Sewa S. Legha's Published Works

Published Works

What Schools Are Affiliated With Sewa S. Legha?

Sewa S. Legha's AcademicInfluence.com Rankings